title: Therapy of chronic myelogenous leukaemia with interferons.
abstract: Therapy of Philadelphia positive chronic myelogenous leukaemia (CML Ph1) with alpha interferon (IFN-alpha) resulted in a high frequency of haematological remissions. Effective suppression of the malignant Ph1 clone and concomitant partial or complete restoration of normal haemopoiesis is reproducibly noted in a proportion (30%-50%) of the patients. This and the low incidence of blast crisis underscore the profound effect this therapy has on the disease. Marked heterogeneity in the response to IFN-alpha was noted as well, and sensitivity or resistance to interferon was phenotypically indistinguishable. Studies of the IFN-resistant disease failed to disclose alteration in IFN receptors or in IFN-inducible genes and are suggestive, therefore, of a limited alteration in IFN-induced intracellular pathways.
authors.affiliation: University of Texas M.D. Anderson Cancer Center, Houston 77030.
authors.forename: M
authors.initials: M
authors.lastname: Talpaz
authors.forename: R
authors.initials: R
authors.lastname: Kurzrock
authors.forename: H
authors.initials: H
authors.lastname: Kantarjian
authors.forename: J
authors.initials: J
authors.lastname: Gutterman
mesh_terms: D006801:Humans; D066298:In Vitro Techniques; D007370:Interferon Type I / Q000627:therapeutic use*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000628:therapy*; D012074:Remission Induction
chemical_list: D007370:Interferon Type I